The Board of Directors of Astec LifeSciences Limited met on April 27, 2026, to approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. For the quarter ended March 31, 2026, the company reported consolidated total income of ₹104.91 Crore, representing a decrease of 15.88% compared to ₹124.72 Crore in the previous quarter (Q3 FY26) and a 12.23% decline from ₹119.53 Crore in the same quarter last year (Q4 FY25). The company reported a consolidated net loss of ₹23.47 Crore for Q4 FY26, which is an increase in loss compared to the ₹13.97 Crore loss in the previous quarter and the ₹16.09 Crore loss in the corresponding quarter of the previous year. The following table summarizes the financial performance for the period:

Astec LifeSciences Limited, a subsidiary of Godrej Agrovet Limited, is a leading Indian manufacturer of agrochemical active ingredients and intermediate products. The company operates in the enterprise and Contract Development and Manufacturing Organization (CDMO) segments, focusing on pesticides and specialty chemicals. In early 2026, the company underwent a significant board restructuring, including the voluntary retirement of Chairman Mr. Nadir Godrej and the appointment of Mr. Vishal Sharma as the new Chairperson. During 2025, the company successfully completed a ₹249.35 Crore rights issue to strengthen its financial position. Major institutional investors in the company include the Singaporean state-owned investment firm Temasek and Nippon Life India Small Cap Fund, while the Godrej group remains the dominant promoter with a holding of approximately 71.97% as of December 2025.